Pathology Laboratories, Inc. (PathLabs) is pleased to announce that we are bringing the STD (Sexually Transmitted Disease) testing for Chlamydia trachomatis (CT), Neisseria gonorrhea (NG), and Trichomonas vaginalis (TV) of urine specimens in-house effective December 27, 2022.

As a result of internalizing this testing, there are updates to our Urine STD tests; specifically for methodology, decreased analytic time, new collection devices, longer stability, and certain EMR code changes. In addition, Urine STD testing is no longer gender specific. However, an order code has been established for a male test for Trichomonas, using a swab collection device.

All testing updates are disclosed in the context of this publication and the chart provided below.

Pathology Laboratories, Inc. (PathLabs) is pleased to announce we will bring HPV, Pap, and STD (Sexually Transmitted Disease) Swab testing for Chlamydia trachomatis (CT), Neisseria gonorrhea (NG), and Trichomonas vaginalis (TV) in-house, effective Thursday, March 2, 2023.

As a result of internalizing this testing, PathLabs is in the process of updating our HPV, Pap, and STD Swab tests; specifically, to accommodate an expanded test menu, introduce a new methodology for molecular testing, convey decreased analytic times, present a new collection device for the Roche platform, and initiate EMR code changes.

As of June 12th, we are converting to a new Cytology/Histology Requisition (version 05/2023), shown at the end of this publication, to be used for ordering Cytology, Histology and Molecular testing. PathLabs’ sales team and supply department will be distributing the new requisition beginning next week.

All testing updates are disclosed in the context of this publication and provided in further detail in the charts below. All changes are marked in bright blue.